Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Mevo Health vs SkyRx

Mevo Health
Graded #326

Higher grade

vs+1.3000000000000043
SkyRx
Graded #355

Lower grade

The verdict

Mevo Health takes it — 60.2/100 to 58.9/100, but only just.

Mevo Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mevo Health (Mevo Health LLC, Delaware) is a direct-pay telehealth platform offering compounded semaglutide and tirzepatide in both injection and oral-tablet forms — a rare both-routes, both-molecules menu. SkyRx is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
56
56
Dose & formulationMevo Health +12
83
71
Clinical oversightSkyRx +1
67
68
Labs & monitoringEven
52
52
FulfillmentSkyRx +7
57
64
Contract termsEven
20
20
Mevo Health · left barSkyRx · right bar

The numbers

MetricMevo HealthSkyRx
WeighScore60.2/10058.9/100
GradeCC
Scorecard rank#326#355
Semaglutide$199/mo (all doses, compounded)$199/mo (all doses, 12-month plan, compounded)
Tirzepatide$259/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Mevo Health

Graded #326 · C

Strengths

  • LegitScript verification badge on multiple pages
  • Publishes the FDA compounded-medication disclaimer
  • Four named board-certified physicians disclosed (Wasef, Suppa, Sakla, Chikando)
  • Both semaglutide and tirzepatide in injection and oral-tablet forms — rare in DTC
  • Public entry-level pricing surfaced

Where it loses points

  • States served not listed on any public page
  • Pharmacy partners not named (only '503A U.S. compounding pharmacies' with unlabeled logos)
  • No formal Medical Director role disclosed
  • Only 'as low as' entry pricing shown — no per-dose itemization
  • No SOC 2 certification claimed
SkyRx

Graded #355 · C

Strengths

  • All-inclusive 199 dollars per month covers medication, supplies, doctor visit and shipping
  • Offers both injectable and oral semaglutide, dispensed by FDA-registered 503B pharmacies
  • Same-day shipping for orders before 2pm ET in temperature-controlled packaging

Where it loses points

  • 199 dollars pricing requires a 12-month subscription paid upfront
  • Tirzepatide only listed as coming soon
  • GLP-1s not yet available in all 50 states; specific states not listed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard